Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma

Why is BP stock surging amid Shell merger talks? How will Fannie Mae treat crypto assets in mortgages? Why is Bumble cutting 30% of its workforce? What impact will Fed’s capital rule changes have? How did Zohran Mamdani’s win affect NYC real estate? Why are Tesla sales dropping in Europe? How are tariff tensions affecting Fed rate decisions?

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma

benzinga.com/markets/large-cap/25/06/46102291/biogen-ionis-partnered-drug-shows-benefit-in-children-with-spinal-muscular-atrophy-previously-t

Biogen Inc. (NASDAQ:BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for spinal muscular atrophy (SMA).
Biogen licensed the global development, manufacturing and…

This story appeared on benzinga.com, 2025-06-25 18:53:39.